Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

The finest minds from the pharma firmament will also be sharing insights on the changing landscape and on the new imperatives ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...

We have already seen the first wave of AI-powered dangers. Deepfakes, bot accounts, and algorithmic manipulation on social ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

The molecule is also being tested in over 100 vaccine clinical trials. Rising QS-21 demand from the pharmaceutical industry ...

Sarah O’Keeffe recounts her fulfilling career path with Eli Lilly from employee to Senior Vice President, Product Research ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...

Today, adoption of digital health faces some of the same barriers — scepticism, budget limitations, high expectations, and a ...

COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results ...